-2%
Erenzo contains roxadustat, a first-in-class, orally administered HIF-PH inhibitor. It promotes erythropoiesis by:
- Increasing endogenous erythropoietin (EPO) production.
- Improving iron regulation.
- Counteracting the suppressive effects of inflammation on hemoglobin synthesis and red blood cell production by reducing hepcidin levels.

